Design Therapeutics Inc - Asset Resilience Ratio
Design Therapeutics Inc (DSGN) has an Asset Resilience Ratio of 90.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Design Therapeutics Inc's Asset Resilience Ratio has changed over time. Check Design Therapeutics Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Design Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see DSGN stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $190.88 Million | 90.14% |
| Total Liquid Assets | $190.88 Million | 90.14% |
Asset Resilience Insights
- Very High Liquidity: Design Therapeutics Inc maintains exceptional liquid asset reserves at 90.14% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Design Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Design Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Design Therapeutics Inc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Design Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 88.43% | $222.91 Million | $252.09 Million | -1.55pp |
| 2023-12-31 | 89.97% | $260.60 Million | $289.64 Million | +0.89pp |
| 2022-12-31 | 89.08% | $303.89 Million | $341.14 Million | +67.19pp |
| 2021-12-31 | 21.89% | $85.50 Million | $390.56 Million | -70.43pp |
| 2020-12-31 | 92.32% | $33.71 Million | $36.52 Million | -- |
About Design Therapeutics Inc
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potenti… Read more